ARDS News and Press, Aridis Pharmaceuticals Inc. From 01/02/20

SAN JOSE, Calif. , Jan. 2, 2020 /PRNewswire/ --  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infection...

Amarin ( AMRN ) is fast approaching a significant event as the company’s lawsuit against a couple of generic drug makers is scheduled for trial on January 13, 2020. The main counter parties in this case are Dr. Reddy’s Laboratories (RDY), Hikma Pharmaceuticals (HKMPF) and Teva (T...

Gainers: Neovasc (NASDAQ: NVCN )  +70% . More news on: Neovasc Inc., Inpixon, FuelCell Energy, Inc., Stocks on the move, Read more ...

Ultra-thinly traded Aridis Pharmaceuticals ( ARDS +43.3% ) is up on a 31x surge in volume, albeit on turnover of only 193K shares, in apparent response to its disclosure that it has developed a monoclonal antibody (mAb) discovery and production technology called APEX that it says maximiz...

Wainright analyst Vernon Bernardino starts Aridis Pharma (NASDAQ: ARDS ) at Buy with a $7 price target, implying  67% upside . More news on: Aridis Pharmaceuticals, Inc., , Healthcare stocks news, Read more ...

Aridis Pharmaceuticals (NASDAQ: ARDS ): Q3 GAAP EPS of -$0.87 in-line. More news on: Aridis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN JOSE, Calif. , Nov. 13, 2019 /PRNewswire/ --  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infectio...

The FDA has a history of stepmotherly behaviour with Amarin (AMRN). We saw it between 2013 and 2015, when the FDA issued a CRL to Amarin when the company asked for a very reasonable label expansion - and the FDA took an entire year to even issue the CRL. The saga of those sordid years can be...

SAN JOSE, Calif. , Oct. 11, 2019 /PRNewswire/ --  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has appointed...

SAN JOSE, Calif. , Sept. 30, 2019 /PRNewswire/ --  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has consumma...